Der var ingen relevant stigning i eksponeringen for nilotinib, når dosisblev øget fra 400 mg to gange dagligt til 600 mg to gange dagligt.
There was no relevant increase in exposure to nilotinib when the dose was increased from 400 mg twice daily to 600 mg twice daily.